The inhibitors used were (1) G9a/GLP inhibitors, BIX01294 and UNC0638, which are compounds that selectively inhibit an enzyme that methylates histone H3 lysine 9 and are known to negatively regulate transcription [25, 26]; (2) Ezh2 and Ezh1/Ezh2 inhibitors: EPZ011989 and UNC1999, which are compounds that selectively inhibit enzymes that add up to three methyl groups on lysine 27 of histone H3, particularly H3K27me3, the most important epi-marker for cancer diseases [27, 28]. Here, EZH1 is linked to cancer.